[fusion_builder_container hundred_percent=”no” equal_height_columns=”no” menu_anchor=”” hide_on_mobile=”small-visibility,medium-visibility,large-visibility” class=”” id=”” background_color=”” background_image=”” background_position=”center center” background_repeat=”no-repeat” fade=”no” background_parallax=”none” parallax_speed=”0.3″ video_mp4=”” video_webm=”” video_ogv=”” video_url=”” video_aspect_ratio=”16:9″ video_loop=”yes” video_mute=”yes” overlay_color=”” video_preview_image=”” border_color=”” border_style=”solid” padding_top=”” padding_bottom=”” padding_left=”” padding_right=”” type=”legacy”][fusion_builder_row][fusion_builder_column type=”4_5″ layout=”1_1″ background_position=”left top” background_color=”” border_color=”” border_style=”solid” border_position=”all” spacing=”yes” background_image=”” background_repeat=”no-repeat” padding_top=”” padding_right=”” padding_bottom=”” padding_left=”” margin_top=”0px” margin_bottom=”0px” class=”” id=”” animation_type=”” animation_speed=”0.3″ animation_direction=”left” hide_on_mobile=”small-visibility,medium-visibility,large-visibility” center_content=”no” last=”false” min_height=”” hover_type=”none” link=”” border_sizes_top=”” border_sizes_bottom=”” border_sizes_left=”” border_sizes_right=”” first=”true” spacing_right=”3.2%”][fusion_text columns=”” column_min_width=”” column_spacing=”” rule_style=”default” rule_size=”” rule_color=”” content_alignment_medium=”” content_alignment_small=”” content_alignment=”” hide_on_mobile=”small-visibility,medium-visibility,large-visibility” sticky_display=”normal,sticky” class=”” id=”” margin_top=”” margin_right=”” margin_bottom=”” margin_left=”” font_size=”” fusion_font_family_text_font=”” fusion_font_variant_text_font=”” line_height=”” letter_spacing=”” text_color=”” animation_type=”” animation_direction=”left” animation_speed=”0.3″ animation_offset=””]
This page lists RIAT restorations to date as well as proposed RIAT projects.
[/fusion_text][fusion_title margin_top=”” margin_bottom=”” hide_on_mobile=”small-visibility,medium-visibility,large-visibility” class=”” id=”” size=”2″ content_align=”left” style_type=”default” sep_color=””]
Completed RIAT restorations
[/fusion_title][fusion_table fusion_table_type=”1″ fusion_table_rows=”8″ fusion_table_columns=”4″ hide_on_mobile=”small-visibility,medium-visibility,large-visibility” class=”” id=”” animation_type=”” animation_direction=”left” animation_speed=”0.3″ animation_offset=””]
| Trial | Intervention(s) studied | Original publication | RIAT restoration |
|---|---|---|---|
| “8-way” Bendectin Study | Doxylamine, Pyridoxine and Dicyclomine | unpublished – invisible | 2017 |
| Paroxetine study 329 continuation phase | Paroxetine, imipramine, and placebo | 2001 | 2016 |
| Paroxetine study 329 | Paroxetine, imipramine, and placebo | 2001 | 2015 |
| CEA Second-Look Trial | ‘Second-look’ surgery with intention to remove any recurrence discovered | unpublished – invisible | 2014 |
| B1Y-MC-HCJE | Fluoxetine for acute treatment of depression in children and adolescents | 2002 | 2022 (full text PDF) |
| B1Y-MC-X065 | Fluoxetine in children and adolescents with depression | 1997 | 2022 (full text PDF) |
| FOURIER trial | Evolocumab and clinical outcomes in patients with cardiovascular disease | 2017 | 2022 |
| Study PRGF (BTI-01-EC/07/ART) | Plasma Rich in Growth Factors (PRGF-Endoret) in the short-term treatment of symptomatic knee osteoarthritis | 2012 | 2023 |
[/fusion_table][fusion_separator style_type=”none” hide_on_mobile=”small-visibility,medium-visibility,large-visibility” class=”” id=”” sep_color=”” top_margin=”” bottom_margin=”” border_size=”” icon=”” icon_circle=”” icon_circle_color=”” width=”” alignment=”center” /][fusion_title margin_top=”” margin_bottom=”” hide_on_mobile=”small-visibility,medium-visibility,large-visibility” class=”” id=”” size=”2″ content_align=”left” style_type=”default” sep_color=””]
Proposed RIAT restorations
[/fusion_title][fusion_table fusion_table_type=”1″ fusion_table_rows=”9″ fusion_table_columns=”6″ hide_on_mobile=”small-visibility,medium-visibility,large-visibility” class=”” id=”” animation_type=”” animation_direction=”left” animation_speed=”0.3″ animation_offset=””]
| Sponsor & Study | Concern | Point of contact | Data available | Date of entry in RIAT database | Calls to action & Responses |
|---|---|---|---|---|---|
| Sponsor and trial ID: Parke-Davis and Pfizer, Studies 945-210, 945-224, 945-400, 945-430-295, 945-430-306, 9451008
Title: A Double-Blind Placebo-Controlled Trial of Gabapentin for Treatment of Painful Diabetic Peripheral Neuropathy; Double-Blind, Randomized, Placebo-Controlled, Parallel Groups, Multi-Center Trial to Determine the Efficacy and Safety of Neurontin (Gabapentin) in Subjects with Peripheral Neuropathy (Post-Herpetic Neuralgia); A Double-Blind Placebo-Controlled Trial with 3 Doses of Gabapentin for Treatment of Painful Diabetic Neuropathy; A Double Blind Placebo Controlled Trial of Gabapentin for the Treatment of Patients Exhibiting Symptoms of Neuropathic Pain; A Double-Blind Placebo Controlled Trial of Gabapentin for the Treatment of Post Herpetic Neuralgia; A 15 Week Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Multicenter Study of Neurontin (Gabapentin) for Efficacy and Quality of Life in Patients with Painful Diabetic Peripheral Neuropathy Study dates: 1996-2003 |
Distortion (misreporting) | Evan Mayo-Wilson | CSRs, IPD, Protocols and blank CRFs | August 30, 2019 | August 30, 2019 Call to Action |
| Sponsor and trial ID: National Institute of Mental Health (NIMH) study NCT00021528
Title: Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Study dates: 2001 to 2006 |
Distortion (misreporting) | H. Edmund Pigott | IPD, protocol, and SAP | March 13, 2019 | March 6, 2019 Call to Action |
| Sponsor and trial ID: Merck study V501-015 NCT00092534
Title: A Randomized Worldwide, Placebo-Controlled, Double-Blind Study to Investigate the Safety, Immunogenicity, and Efficacy on the Incidence of HPV 16-/18-Related CIN 2/3 or Worse of the Quadrivalent HPV (Types 6, 11, 16, 18] Ll Virus-Like Particle (VLP) Vaccine in 16- to 23-Year-Old Women – The FUTURE II Study (Females United to Unilaterally Reduce Endo/Ectocervical Disease) Study dates: 2002 to 2007 |
Invisibility (unpublished methodology) and distortion (misreporting) | Peter Doshi | CSR | January 11, 2019 | Jan 11, 2019 Call to Action |
| Sponsor and trial ID: Merck study V501-019 NCT00090220
Title: Safety, Immunogenicity, and Efficacy of GARDASIL™ (Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) in Study dates: 2004 to 2009 |
Invisibility (unpublished methodology) and distortion (misreporting) | Peter Doshi | CSR | January 11, 2019 | Jan 11, 2019 Call to Action |
| Sponsor and trial ID: Forest Laboratories’ study CIT-MD-18
Title: A randomized, placebo-controlled trial of citalopram for the treatment of major depression in children and adolescents Study dates: 1999 to 2002 |
Distortion (misreporting) | Leemon McHenry | Protocol & partial CSR | June 15, 2018 | June 13, 2018 Call to Action |
| Sponsor and trial ID: Pfizer trial 050-113
Title: The Effects of Sertraline Compared with Placebo on the Body Weights of Patients with Non-Insulin-Dependent Diabetes Mellitus Study dates: Oct 1998 to Jan 1992 |
Invisible (unpublished) | Tarang Sharma | ~100 pages from main body of CSR | June 15, 2018 | June 8, 2018 Call to Action |
| Sponsor and trial ID: US National Institute of Mental Health (NIMH) study NCT00006286
Title: Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents with Depression Study (TADS) randomized controlled trial Study dates: 2000 to 2003 |
Distortion (misreporting) | Jon Jureidini | Protocol & IPD | June 4, 2018 | May 28, 2018 Call to Action |
[/fusion_table][/fusion_builder_column][fusion_builder_column type=”1_5″ layout=”1_5″ spacing=”” center_content=”no” link=”” target=”_self” min_height=”” hide_on_mobile=”small-visibility,medium-visibility,large-visibility” class=”” id=”” background_color=”” background_image=”” background_position=”left top” background_repeat=”no-repeat” hover_type=”none” border_color=”” border_style=”solid” border_position=”all” padding_top=”” padding_right=”” padding_bottom=”” padding_left=”” margin_top=”” margin_bottom=”” animation_type=”” animation_direction=”left” animation_speed=”0.3″ animation_offset=”” last=”true” border_sizes_top=”0″ border_sizes_bottom=”0″ border_sizes_left=”0″ border_sizes_right=”0″ first=”false” spacing_left=”0.8%”][fusion_flip_boxes columns=”1″ icon=”” icon_color=”#333333″ circle=”no” circle_color=”” circle_border_color=”” icon_flip=”” icon_rotate=”” icon_spin=”no” image=”” image_width=”” image_height=”” hide_on_mobile=”small-visibility,medium-visibility,large-visibility” class=”” id=”” image_max_width=””][fusion_flip_box title_front=”Oops” title_back=”Report a trial” text_front=”Know of an unpublished or misreported trial?” background_color_front=”#ccff99″ title_front_color=”” text_front_color=”” background_color_back=”#99cc66″ title_back_color=”#000000″ text_back_color=”#000000″ border_size=”” border_color=”” border_radius=”” icon=”fa-exclamation-triangle” icon_color=”” circle=”” circle_color=”” circle_border_color=”” icon_flip=”” icon_rotate=”” icon_spin=”” image=”” image_max_width=”35″ image_height=”35″ animation_type=”” animation_direction=”left” animation_speed=”0.1″ animation_offset=””]
Tell us about it. We will collate the responses and publish a summary on the website
[/fusion_flip_box][/fusion_flip_boxes][/fusion_builder_column][/fusion_builder_row][/fusion_builder_container]